These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9484866)

  • 1. Grepafloxacin--focus on respiratory infections.
    Geddes AM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
    [No Abstract]   [Full Text] [Related]  

  • 2. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
    Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
    [No Abstract]   [Full Text] [Related]  

  • 3. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 4. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of grepafloxacin.
    Wiedemann B; Heisig P
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():19-25. PubMed ID: 9484869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
    Sato A; Kitazawa H; Chida K; Hayakawa H; Iwata M
    Drugs; 1995; 49 Suppl 2():253-5. PubMed ID: 8549321
    [No Abstract]   [Full Text] [Related]  

  • 7. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of Baytril (Bay Vp 2674) on young turkeys with respiratory tract infections].
    Braunius WW
    Tijdschr Diergeneeskd; 1987 May; 112(9):531-3. PubMed ID: 3603541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Grepafloxacin (Raxar)].
    Friis HM
    Ugeskr Laeger; 1998 Jul; 160(30):4438-41. PubMed ID: 9691842
    [No Abstract]   [Full Text] [Related]  

  • 12. New fluoroquinolone antibiotics.
    Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
    Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686
    [No Abstract]   [Full Text] [Related]  

  • 14. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 15. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 16. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 17. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B; Dutchman DA; Pettit R; Maroli A
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S; Swarz H; Breisch SA; Maroli AN
    Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of grepafloxacin compared with other fluoroquinolones.
    Stahlmann R; Schwabe R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.